HomeCompareFRES vs EPRT

FRES vs EPRT: Dividend Comparison 2026

FRES yields 235.29% · EPRT yields 3.92%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 FRES wins by $315.55M in total portfolio value
10 years
FRES
FRES
● Live price
235.29%
Share price
$0.85
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$315.61M
Annual income
$171,899,209.13
Full FRES calculator →
EPRT
EPRT
● Live price
3.92%
Share price
$30.77
Annual div
$1.21
5Y div CAGR
29%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$63.4K
Annual income
$12,840.73
Full EPRT calculator →

Portfolio growth — FRES vs EPRT

📍 FRES pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodFRESEPRT
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, FRES + EPRT cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
FRES pays
EPRT pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

FRES
Annual income on $10K today (after 15% tax)
$20,000.00/yr
After 10yr DRIP, annual income (after tax)
$146,114,327.76/yr
EPRT
Annual income on $10K today (after 15% tax)
$332.87/yr
After 10yr DRIP, annual income (after tax)
$10,914.62/yr
At 15% tax rate, FRES beats the other by $146,103,413.14/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of FRES + EPRT for your $10,000?

FRES: 50%EPRT: 50%
100% EPRT50/50100% FRES
Portfolio after 10yr
$157.84M
Annual income
$85,956,024.93/yr
Blended yield
54.46%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EPRT right now

FRES
Analyst Ratings
1
Buy
Consensus: Buy
EPRT
Analyst Ratings
1
Strong
17
Buy
3
Hold
1
Sell
Consensus: Buy
Price Target
$35.50
+15.4% upside vs current
Range: $33.00 — $37.00
Altman Z
1.8
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

FRES buys
0
EPRT buys
0
No recent congressional trades found for FRES or EPRT in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricFRESEPRT
Forward yield235.29%3.92%
Annual dividend / share$2.00$1.21
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%29%
Portfolio after 10y$315.61M$63.4K
Annual income after 10y$171,899,209.13$12,840.73
Total dividends collected$299.93M$37.9K
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusBuyBuy

Year-by-year: FRES vs EPRT ($10,000, DRIP)

YearFRES PortfolioFRES Income/yrEPRT PortfolioEPRT Income/yrGap
1← crossover$34,229$23,529.41$11,205$505.18+$23.0KFRES
2$111,896$75,270.83$12,672$682.46+$99.2KFRES
3$349,693$229,963.68$14,490$930.48+$335.2KFRES
4$1,045,826$671,655.14$16,786$1,282.69+$1.03MFRES
5$2,996,342$1,877,308.05$19,753$1,791.56+$2.98MFRES
6$8,232,794$5,026,707.34$23,677$2,541.64+$8.21MFRES
7$21,716,990$12,907,901.09$29,008$3,672.99+$21.69MFRES
8$55,058,944$31,821,764.79$36,463$5,425.08+$55.02MFRES
9$134,312,616$75,399,545.57$47,238$8,221.57+$134.27MFRES
10$315,613,708$171,899,209.13$63,385$12,840.73+$315.55MFRES

FRES vs EPRT: Complete Analysis 2026

FRESStock

Fresh2 Group Limited, a biotechnology company, researches, develops, markets, and sells multi-cancer screening and detection tests using cancer differentiation analysis technology and device to corporations and life insurance companies in the People's Republic of China. It also offers physical checkup packages, as well as technology services comprising market research, designing, coding, developing, testing, etc. In addition, the company sells genetic testing kits and skin-care products; and owns core technology platforms, as well as engages in technology development and product distribution. Further, it operates an e-commerce platform that connects food suppliers and supermarket operators and restaurant owners. The company was formerly known as AnPac Bio-Medical Science Co., Ltd. and changed its name to Fresh2 Group Limited in April 2023. The company was incorporated in 2010 and is based in New York, New York.

Full FRES Calculator →

EPRTREIT

Essential Properties Realty Trust, Inc., a real estate company, acquires, owns, and manages single-tenant properties in the United States. The company leases its properties to middle-market companies, such as restaurants, car washes, automotive services, medical and dental services, convenience stores, equipment rental, entertainment, early childhood education, grocery, and health and fitness on a long-term basis. As of December 31, 2021, it had a portfolio of 1, 451 properties. The company qualifies as a real estate investment trust for federal income tax purposes. It generally would not be subject to federal corporate income taxes if it distributes at least 90% of its taxable income to its stockholders. The company was founded in 2016 and is headquartered in Princeton, New Jersey.

Full EPRT Calculator →
📬

Get this FRES vs EPRT comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

FRES vs SCHDFRES vs JEPIFRES vs OFRES vs KOFRES vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.